Isabelle Riviere

A leader in cell therapy and cell engineering with 25+ years of experience developing and advancing cell therapy drug candidates from pre-clinical stage to late phase clinical trials and building strong collaborations between academia and industry partners, including CAR T cells, CD34+ hematopoietic cells, embryonic stem cell-derived dopaminergic neurons, and iPS-derived T cells. Brings strong expertise and leadership in CMC enabling studies, clinical drug product manufacturing, quality control and analytics development, vector and gene editing tool manufacturing, quality assurance, compliance, and technology transfer, with a focus on patient access to cell and gene therapy treatments and sustainable models for rare and small patient populations.